创新药物转化研究中ADME的评价

被引：10

作者：

刘瑶 ^{[1
]}

洪岚 ^{[1
]}

余露山 ^{[1
]}

蒋惠娣 ^{[1
]}

陈建忠 ^{[1
]}

孟琴 ^{[2
]}

陈枢青 ^{[1
]}

曾苏 ^{[1
]}

机构：

[1] 浙江大学药学院

[2] 浙江大学化学工程与生物工程学系

来源：

药学学报 | 2011年 / 01期

关键词：

转化研究; 新药研发; 成药性; 药物处置;

D O I：

10.16438/j.0513-4870.2011.01.012

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

新药研发是一复杂的庞大系统工程,所涉及的学科门类众多,研究周期长。而转化研究有助于构建创新药物的基础研究、临床前研究和临床疗效评价直至新药制造和临床应用的系统研发链,顺畅基础医学和生物学与创新药物研发、临床医学之间的信息和研究关联,缩短创新药物从实验室到临床应用的研发周期。在新药研发和临床应用过程中,化合物的体内过程(吸收、分布、代谢、排泄,ADME)是其成药性的重要指标。化合物ADME/T性质在创新药物转化研究中发挥重要作用并贯穿研发过程。因此,在药物设计及新药开发早期就开展药物代谢研究,有利于提高新药研发的成功率,降低新药开发的成本,获得安全、有效的治疗药物。

引用

页码：19 / 29+2 +2

页数：12

共 23 条

[1]

Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations[J] . Lin He,Fan He,Huichang Bi,Jiankang Li,Su Zeng,Hai-Bin Luo,Min Huang.Bioorganic ＆ Medicinal Chemistry Letters . 2010 (20)

[2] Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity [J].

Meng, Qin .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (06) :733-746

[3] Impact of the Recent Mouse P-Glycoprotein Structure for Structure-Based Ligand Design [J].

Klepsch, Freya ;

Ecker, Gerhard F. .

MOLECULAR INFORMATICS, 2010, 29 (04) :276-286

[4]

A highly sensitive and robust UPLC–MS with electrospray ionization method for quantitation of taxifolin in rat plasma[J] . Xiaodan Wang,Hongjun Xia,Feng Xing,Guifeng Deng,Qi Shen,Su Zeng.Journal of Chromatography B . 2009 (18)

[5]

Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp[J] . Xiao-dan Wang,Min-xin Meng,Ling-bo Gao,Ting Liu,Qiang Xu,Su Zeng.International Journal of Pharmaceutics . 2009 (1)

[6] Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes [J].

Liu, Z. H. ;

Zeng, S. .

TOXICOLOGY LETTERS, 2009, 187 (03) :131-136

[7]

ADME pharmacogenetics: current practices and future outlook[J] . Grossman.Expert Opinion on Drug Metabolism ＆ Toxicology . 2009 (5)

[8]

Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin[J] . Kenneth C. Cundy,Srikonda Sastry,Wendy Luo,Joan Zou,Tristen L. Moors,Daniel M. Canafax.Journal of Clinical Pharmacology . 2008 (12)

[9]

Structure–activity relationships of new inhibitors of breast cancer resistance protein （ABCG2）[J] . Anne Pick,Henrik Müller,Michael Wiese.Bioorganic ＆ Medicinal Chemistry . 2008 (17)

[10] Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9 [J].

Chen, Yakun ;

Xie, Shenggu ;

Chen, Shuqing ;

Zeng, Su .

BIOCHEMICAL PHARMACOLOGY, 2008, 76 (03) :416-425

← 1 2 3 →